# A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT04244656** · PHASE1 · TERMINATED · sponsor: **CRISPR Therapeutics AG** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CTX120

## Key facts

- **NCT ID:** NCT04244656
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-22
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Patients to be followed up in the CRSP-ONC-LTF study
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04244656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04244656, "A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04244656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*